Skip to search formSkip to main contentSkip to account menu

Ladostigil

National Institutes of Health

Related topics

Related topics

1 relation
Ladostigil Tartrate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
TV 3326 for Alzheimer’s dementia: a novel multimodal ChE and MAO inhibitors to mitigate Alzheimer’s‐like neuropathology
Alzheimer’s disease (AD) is one of the most prevalent neurodegenerative disorders and a well‐recognized cause of dementia with… 
2019
2019
Low-dose ladostigil for mild cognitive impairment
Objective Ladostigil reduces oxidative stress and microglial activation in aging rats. We assessed its safety and potential… 
Review
2014
Review
2014
Monoamine oxidase inhibitors: promising therapeutic agents for Alzheimer's disease (Review).
Activated monoamine oxidase (MAO) has a critical role in the pathogenesis of Alzheimer's disease (AD), including the formation of… 
Review
2007
Review
2007
Induction of Neurotrophic Factors GDNF and BDNF Associated with the Mechanism of Neurorescue Action of Rasagiline and Ladostigil
Parkinson's disease (PD) and Alzheimer's disease (AD) are the most common neurodegenerative disorders, although there is no drug… 
Review
2007
Review
2007
Treatment consideration and manifest complexity in comorbid neuropsychiatric disorders
Psychiatric disorders may co-occur in the same individual. These include, for example, substance abuse or obsessive-compulsive… 
Highly Cited
2006
Highly Cited
2006
A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo‐APP translation and processing
The recent therapeutic approach in which drug candidates are designed to possess diverse pharmacological properties and act on… 
Review
2006
Review
2006
Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil
The recent therapeutic approach in which drug candidates are designed to possess diverse pharmacological properties and act on… 
Review
2005
Review
2005
Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases
2005
2005
The neurochemical and behavioral effects of the novel cholinesterase–monoamine oxidase inhibitor, ladostigil, in response to L‐dopa and L‐tryptophan, in rats
The novel drugs, ladostigil (TV3326) and TV3279, are R and S isomers, respectively, derived from a combination of the carbamate… 
Highly Cited
2005
Highly Cited
2005
Effect of chronic treatment with ladostigil (TV-3326) on anxiogenic and depressive-like behaviour and on activity of the hypothalamic–pituitary–adrenal axis in male and female prenatally stressed…
ObjectiveThe aim of the study is to investigate the effect of ladostigil, a cholinesterase and brain-selective monoamine oxidase… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)